General Information of Drug (ID: DM7JZ53)

Drug Name
L-4-OXALYSINE
Synonyms I-677; Oxalysine-L; O-(2-Aminoethyl)-L-serine
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 148.16
Logarithm of the Partition Coefficient (xlogp) -4.5
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C5H12N2O3
IUPAC Name
(2S)-2-amino-3-(2-aminoethoxy)propanoic acid
Canonical SMILES
C(COC[C@@H](C(=O)O)N)N
InChI
InChI=1S/C5H12N2O3/c6-1-2-10-3-4(7)5(8)9/h4H,1-3,6-7H2,(H,8,9)/t4-/m0/s1
InChIKey
SLTGLTLBIVDQKE-BYPYZUCNSA-N
Cross-matching ID
PubChem CID
160555
ChEBI ID
CHEMBL72341
CAS Number
15219-97-3
TTD ID
D0J5DL
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone synthesis (Histone synth) TTNRF4L NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008265)
2 Immunostimulatory action of L-4-oxalysine counteracts immunosuppression induced by alpha-fetoprotein. Eur J Pharmacol. 1998 Jun 12;351(1):105-11.